ArticleFrontiers in aging neuroscience2025
Integrated analysis of N-glycosylation and Alzheimer's disease: identifying key biomarkers and mechanisms.
Article in Frontiers in aging neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- N-Glycosylation and Alzheimer's disease: A 2001-2025 global bibliometric landscape revealing emerging diagnostic trends.Journal of Alzheimer's disease reportsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Alzheimer's disease (AD) is the most prevalent cause of dementia in the elderly, imposing a significant societal burden. Current therapeutic approaches primarily address symptoms, underscoring the critical need to elucidate its pathogenesis and identify robust early biomarkers. N-glycosylation, a critical post-translational modification, is dysregulated in neurodegenerative disorders, yet its role in AD and diagnostic potential remain underexplored. Objective: This investigation aimed to characterize the interplay between N-glycosylation and AD through multi-dimensional bioinformatics analysis, identify core differentially expressed genes (DEGs) associated with this crosstalk, and evaluate their diagnostic efficacy in early AD detection. Methods: A bibliometric analysis of Web of Science literature spanning 2001-2025 was performed using VOSviewer, CiteSpace, and R. Transcriptomic data were analyzed with LIMMA to identify DEGs. Feature prioritization and molecular interaction decoding were achieved through Lasso, Random Forest, XGBoost, and SHAP analysis. Results: Bibliometric analysis highlighted a shift toward granular molecular mechanisms, with "bisecting GlcNAc" and "GNT-III (MGAT3)" emerging as key research topics. Differential expression profiling identified 6,845 DEGs, including TMEM59, MLEC, and MAX. Machine learning algorithms consistently prioritized these three genes as core N-glycosylation-related biomarkers, alongside APP as a key associated molecule. Among transcription factors, MAX was identified as a central regulator, with a subset of 8 factors (including MAX and BRD9) pinpointed as critical modulators of N-glycosylation and glial activation in AD. Diagnostic models demonstrated strong performance: logistic regression achieved an AUC of 0.947 with MAX, APP, and MLEC; Random Forest and XGBoost attained perfect AUC = 1.0 in primary analyses; and a clinical nomogram integrating core genes yielded an AUC of 0.899. SHAP analysis confirmed MAX, APP, MLEC, and TMEM59 as top predictors, revealing significant positive interactions between MLEC and TMEM59 ( Conclusion: MAX, MLEC, and TMEM59 represent key N-glycosylation-linked diagnostic biomarkers for AD. This integrative framework provides novel insights into AD pathogenesis and lays the foundation for personalized diagnostic tools and therapies, warranting experimental validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.